While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with these treatments, calling for the identification of clinical and, ideally modifiable, predictors of efficacy. Body composition phenotypes may reflect aspects of patients' immunology and thereby their ability to respond to ICIs. This study aims to explore the possible association between pre-treatment body composition phenotypes, tumour response, and clinical outcomes in patients receiving first-line pembrolizumab monotherapy for advanced NSCLC.

中文翻译：

---

接受一线 pembrolizumab 治疗的肺癌患者体成分紊乱：一项多中心观察性研究


虽然免疫检查点抑制剂 （ICI） 正在越来越多地重塑非小细胞肺癌 （NSCLC） 的治疗格局，但只有有限比例的患者通过这些治疗获得了相关且持久的益处，因此需要确定临床疗效的预测因子，理想情况下是可修改的疗效预测因子。身体成分表型可能反映了患者免疫学的各个方面，从而反映了他们对 ICI 的反应能力。本研究旨在探讨接受一线 pembrolizumab 单药治疗晚期 NSCLC 的患者治疗前体成分表型、肿瘤反应和临床结果之间的可能关联。